1
|
Collignon C, Benaboud S, Gana I, Bendavid M, Fournier B, Oualha M, de Marcellus C. Pharmacokinetic of ceftazidime-avibactam in a critically ill patient under high-volume continuous venovenous haemodiafiltration: A first paediatric case report. Br J Clin Pharmacol 2024; 90:890-894. [PMID: 38178624 DOI: 10.1111/bcp.15993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 12/01/2023] [Accepted: 12/16/2023] [Indexed: 01/06/2024] Open
Abstract
Ceftazidime-avibactam is a novel cephalosporin/B-lactamase inhibitor developed in the context of increasing resistance. This case reports the pharmacokinetics of ceftazidime-avibactam in a critically ill child under continuous renal replacement (CRRT) therapy for fluid overload. The patient was a 6-month-old female with sepsis due to bloodstream infection to Stenotrophomonas maltophilia following stem cell transplantation for severe combined immunodeficiency. CRRT was started on Day 2. Concentrations have been monitored using liquid chromatography-tandem mass spectrometry. Treatment was given every 8 h with a 2 h infusion of 30-7,5 mg/kg and did not reach pharmacokinetic/pharmacodynamic targets. Total clearance was respectively 1.7 and 3.02 L/h, with CRRT clearance respectively 28.8%-60% for ceftazidime and 14%-33% for avibactam. Those clearances are higher than reported in adult literature leading to a risk of treatment failure and emerging resistance. This supports the benefit of monitoring antimicrobial therapy under CRRT and the necessity to assess higher dosing or continuous infusion of ceftazidime-avibactam.
Collapse
Affiliation(s)
- Charlotte Collignon
- Pediatric Intensive Care Unit, APHP University Hospital Necker-Enfants Malades, Paris, France
| | - Sihem Benaboud
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Department of Clinical Pharmacology, Cochin Hospital, Paris Descartes University, Paris Descartes University, Paris, France
| | - Inès Gana
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Department of Clinical Pharmacology, Cochin Hospital, Paris Descartes University, Paris Descartes University, Paris, France
| | - Matthieu Bendavid
- Pediatric Intensive Care Unit, APHP University Hospital Necker-Enfants Malades, Paris, France
| | - Benjamin Fournier
- Pediatric Hematology-Immunology and Rheumatology Unit, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Mehdi Oualha
- Pediatric Intensive Care Unit, APHP University Hospital Necker-Enfants Malades, Paris, France
- Université de Paris, Paris, France
| | - Charles de Marcellus
- Pediatric Intensive Care Unit, APHP University Hospital Necker-Enfants Malades, Paris, France
| |
Collapse
|
2
|
Thy M, Urien S, Bouazza N, Foissac F, Gana I, Bille E, Béranger A, Toubiana J, Berthaud R, Lesage F, Renolleau S, Tréluyer JM, Benaboud S, Oualha M. Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy. Clin Pharmacokinet 2022; 61:1609-1621. [PMID: 36251162 DOI: 10.1007/s40262-022-01179-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/06/2022] [Indexed: 01/31/2023]
Abstract
BACKGROUND AND OBJECTIVE We aimed to develop a meropenem population pharmacokinetic model in critically ill children receiving continuous renal replacement therapy and simulate dosing regimens to optimize patient exposure. METHODS Meropenem plasma concentration was quantified by high-performance liquid chromatography. Meropenem pharmacokinetics was investigated using a non-linear mixed-effect modeling approach. Monte Carlo simulations were performed to compute the optimal scheme of administration, according to the target of a 100% inter-dose interval time in which concentration is one to four times above the minimum inhibitory concentration (100% fT>1-4×MIC). RESULTS A total of 27 patients with a median age of 4 [interquartile range 0-11] years, a median body weight of 16 [range 7-35] kg receiving continuous renal replacement therapy were included. Concentration-time courses were best described by a one-compartment model with first-order elimination. Body weight (BW) produced significant effects on volume of distribution (V) and BW and continuous renal replacement therapy effluent flow rate (Qeff) produced significant effects on clearance (CL): [Formula: see text] and [Formula: see text], where Vpop and CLpop estimates were 32.5 L and 5.88 L/h, respectively, normalized to a 70-kg BW and median Qeff at 1200 mL/h. Using this final model and Monte Carlo simulations, for patients with Qeff over 1200 mL/h, meropenem continuous infusion was adequate in most cases to attain 100% fT>1-4xMIC. For bacterial infections with a low minimum inhibitory concentration (≤2 mg/L), meropenem intermitent administration was appropriate for patients weighing more than 20 kg with Qeff <500 mL/h and for patients weighing more than 10 kg with Qeff <100 mL/h. CONCLUSIONS Meropenem exposure in critically ill children receiving continuous renal replacement therapy needs dosing adjustments to the minimum inhibitory concentration that take into account body weight and the continuous renal replacement therapy effluent flow rate.
Collapse
Affiliation(s)
- Michael Thy
- Service de Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, AP-HP, Université Paris Cité, 75018, Paris, France.
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université Paris Cité, Paris, France.
| | - Saik Urien
- Unité de Recherche Clinique-Centre d'Investigation Clinique, Hôpital Cochin-Necker, AP-HP, Université Paris Cité, Paris, France
| | - Naim Bouazza
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université Paris Cité, Paris, France
- Unité de Recherche Clinique-Centre d'Investigation Clinique, Hôpital Cochin-Necker, AP-HP, Université Paris Cité, Paris, France
| | - Frantz Foissac
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université Paris Cité, Paris, France
- Unité de Recherche Clinique-Centre d'Investigation Clinique, Hôpital Cochin-Necker, AP-HP, Université Paris Cité, Paris, France
| | - Inès Gana
- Unité de Recherche Clinique-Centre d'Investigation Clinique, Hôpital Cochin-Necker, AP-HP, Université Paris Cité, Paris, France
| | - Emmanuelle Bille
- Service deMmicrobiologieHôpital Necker Enfants-Malades, AP-HP, Université Paris Cité, Paris, France
| | - Agathe Béranger
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université Paris Cité, Paris, France
- Service de Réanimation Chirurgicale Cardiaque Pédiatrique, Hôpital Necker Enfants-Malades, AP-HP, Université de Paris Cité, Paris, France
| | - Julie Toubiana
- Service de Pédiatrie Générale et Infectieuse, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, AP-HP, Université Paris Cité, Paris, France
| | - Romain Berthaud
- Service de Néphrologie Pédiatrique, Centre de Référence MARHEA, Hôpital Necker-Enfants Malades, AP-HP, Université Paris Cité, Paris, France
| | - Fabrice Lesage
- Service de Réanimation et Surveillance Continue Médicochirurgicales, Hôpital Necker Enfants-Malades, AP-HP, Université Paris Cité, Paris, France
| | - Sylvain Renolleau
- Service de Réanimation et Surveillance Continue Médicochirurgicales, Hôpital Necker Enfants-Malades, AP-HP, Université Paris Cité, Paris, France
| | - Jean-Marc Tréluyer
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université Paris Cité, Paris, France
- Service deMmicrobiologieHôpital Necker Enfants-Malades, AP-HP, Université Paris Cité, Paris, France
- Service de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Université Paris Cité, Paris, France
| | - Sihem Benaboud
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université Paris Cité, Paris, France
- Service de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Université Paris Cité, Paris, France
| | - Mehdi Oualha
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université Paris Cité, Paris, France
- Service de Réanimation et Surveillance Continue Médicochirurgicales, Hôpital Necker Enfants-Malades, AP-HP, Université Paris Cité, Paris, France
| |
Collapse
|
3
|
de Cacqueray N, Boujaafar S, Bille E, Moulin F, Gana I, Benaboud S, Hirt D, Béranger A, Toubiana J, Renolleau S, Tréluyer JM, Oualha M. Therapeutic Drug Monitoring of Antibiotics in Critically Ill Children: An Observational Study in a Pediatric Intensive Care Unit. Ther Drug Monit 2022; 44:319-327. [PMID: 35292609 DOI: 10.1097/ftd.0000000000000918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 07/05/2021] [Indexed: 11/26/2022]
Abstract
BACKGROUND Septic critically ill children are at a high risk of inadequate antibiotic exposure, requiring them to undergo therapeutic drug monitoring (TDM). The aim of this study was to describe the use of TDM for antibiotics in critically ill children. METHODS The authors conducted a single-center observational study between June and December 2019, with all children treated with antibiotics in a pediatric intensive care unit located in a French university hospital. Standard clinical and laboratory data were recorded. Blood samples were collected for routine laboratory tests, and plasma antibiotic levels were assayed using validated analytical methods. RESULTS A total of 209 children received antibiotics. TDM was performed in 58 patients (27.8%) who had a greater mean organ dysfunction (according to the International Pediatric Sepsis Consensus Conference) (3 versus 1 in the non-TDM group; P < 0.05) and were treated with antibiotics for longer. A total of 208 samples were analyzed. The median [interquartile range] assay turnaround time was 3 (1-5) days, and 48 (46.2%) of the 104 initial antibiotic concentration values were below the pharmacokinetic/pharmacodynamic targets. A total of 34 (46%) of the 74 off-target TDM measurements available before the end of the antibiotic treatment prompted dose adjustment. This dose adjustment increased the proportion of on-target TDM measurements (70% versus 20% without adjustment). Subsequent measurements of the minimum inhibitory concentration showed that the use of the European Committee on Antimicrobial Susceptibility Testing's epidemiological cutoff values led to underestimation of pharmacokinetic/pharmacodynamic target attainment in 10 cases (20%). CONCLUSIONS TDM seems to be an effective means of optimizing antibiotic exposure in critically ill children. This requires timely plasma antibiotic assays and minimum inhibitory concentration measurements. It is important to define which patients should undergo TDM and how this monitoring should be managed.
Collapse
Affiliation(s)
- Noémie de Cacqueray
- Department of Pediatric Intensive Care Unit, Necker Enfants Malades Hospital, Université de Paris
| | - Sana Boujaafar
- Department of Clinical Pharmacology, Cochin Hospital, Université de Paris
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Université de Paris
| | - Emmanuelle Bille
- Microbiological Laboratory, Necker Enfants Malades Hospital, Université de Paris; and
| | - Florence Moulin
- Department of Pediatric Intensive Care Unit, Necker Enfants Malades Hospital, Université de Paris
| | - Inès Gana
- Department of Clinical Pharmacology, Cochin Hospital, Université de Paris
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Université de Paris
| | - Sihem Benaboud
- Department of Clinical Pharmacology, Cochin Hospital, Université de Paris
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Université de Paris
| | - Déborah Hirt
- Department of Clinical Pharmacology, Cochin Hospital, Université de Paris
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Université de Paris
| | - Agathe Béranger
- Department of Pediatric Intensive Care Unit, Necker Enfants Malades Hospital, Université de Paris
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Université de Paris
| | - Julie Toubiana
- Department of General Pediatrics and Pediatric Infectious Diseases, Necker Enfants Malades Hospital, Université de Paris, Paris, France
| | - Sylvain Renolleau
- Department of Pediatric Intensive Care Unit, Necker Enfants Malades Hospital, Université de Paris
| | - Jean M Tréluyer
- Department of Pediatric Intensive Care Unit, Necker Enfants Malades Hospital, Université de Paris
- Department of Clinical Pharmacology, Cochin Hospital, Université de Paris
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Université de Paris
| | - Mehdi Oualha
- Department of Pediatric Intensive Care Unit, Necker Enfants Malades Hospital, Université de Paris
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Université de Paris
| |
Collapse
|
4
|
Contejean A, Ayral X, Dorlo TPC, Roseboom IC, Yera H, Gana I, Chouchana L, Canouï E, Buffet P, Charlier C. Relapsing leishmanial arthritis: report of a tricky localization and evidence of miltefosine diffusion in synovial fluid. J Antimicrob Chemother 2021; 76:2740-2741. [PMID: 34189571 DOI: 10.1093/jac/dkab218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Accepted: 06/03/2021] [Indexed: 11/12/2022] Open
Affiliation(s)
- Adrien Contejean
- Université de Paris, Faculté de Médecine, F-75006, Paris, France.,Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, F-75014, Paris, France
| | - Xavier Ayral
- Service de Rhumatologie, AP-HP, APHP.CUP, Hôpital Cochin, F-75014, Paris, France
| | - Thomas P C Dorlo
- Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Ignace C Roseboom
- Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Hélène Yera
- Université de Paris, Faculté de Médecine, F-75006, Paris, France.,Laboratoire de Parasitologie, AP-HP, APHP.CUP, Hôpital Cochin, F-75014, Paris, France
| | - Inès Gana
- Service de Pharmacologie, AP-HP, APHP.CUP, Hôpital Cochin, F-75014, Paris, France
| | - Laurent Chouchana
- Centre Régional de Pharmacovigilance, Service de Pharmacologie, AP-HP, APHP.CUP, Hôpital Cochin, F-75014, Paris, France
| | - Etienne Canouï
- Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, F-75014, Paris, France
| | - Pierre Buffet
- Université de Paris, Faculté de Médecine, F-75006, Paris, France
| | - Caroline Charlier
- Université de Paris, Faculté de Médecine, F-75006, Paris, France.,Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, F-75014, Paris, France
| |
Collapse
|
5
|
Hirt D, Oualha M, Pasquiers B, Blanot S, Rubinstazjn R, Glorion C, Messaoudi SE, Drummond D, Lopez V, Toubiana J, Béranger A, Boujaafar S, Zheng Y, Capito C, Winter S, Léger PL, Berthaud R, Gana I, Foissac F, Tréluyer JM, Bouazza N, Benaboud S. Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. Eur J Clin Pharmacol 2021; 77:1687-1695. [PMID: 34160669 DOI: 10.1007/s00228-021-03174-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 06/10/2021] [Indexed: 11/24/2022]
Abstract
PURPOSE This study aimed to characterize pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing scheme. METHODS Children treated with ciprofloxacin were included. Pharmacokinetics were described using non-linear mixed-effect modelling and validated with an external dataset. Monte Carlo simulations investigated dosing regimens to achieve a target AUC0-24 h/MIC ratio ≥ 125. RESULTS A total of 189 children (492 concentrations) were included. A two-compartment model with first-order absorption and elimination best described the data. An allometric model was used to describe bodyweight (BW) influence, and effects of estimated glomerular filtration rate (eGFR) and age were significant on ciprofloxacin clearance. CONCLUSION The recommended IV dose of 10 mg/kg q8h, not exceeding 400 mg q8h, would achieve AUC0-24 h to successfully treat bacteria with MICs ≤ 0.25 (e.g. Salmonella, Escherichia coli, Proteus, Haemophilus, Enterobacter, and Klebsiella). A dose increase to 600 mg q8h in children > 40 kg and to 15 mg/kg q8h (max 400 mg q8h, max 600 mg q8h if augmented renal clearance, i.e., eGFR > 200 mL/min/1.73 m2) in children < 40 kg would be needed for the strains with highest MIC (16% of Pseudomonas aeruginosa and 47% of Staphylococcus aureus). The oral recommended dose of 20 mg/kg q12h (not exceeding 750 mg) would cover bacteria with MICs ≤ 0.125 but may be insufficient for bacteria with higher MIC and a dose increase according bodyweight and eGFR would be needed. These doses should be prospectively confirmed, and a therapeutic drug monitoring could be used to refine them individually.
Collapse
Affiliation(s)
- D Hirt
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France. .,Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France. .,INSERM, U1018, Hôpital de Bicêtre, 78 Rue du Général Leclerc, 94270, Le Kremlin-Bicêtre, France.
| | - M Oualha
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France.,Service de Réanimation et Surveillance Continue Médico-Chirurgicales Pédiatriques, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France
| | - B Pasquiers
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France
| | - S Blanot
- Service de Neurochirurgie, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France
| | - R Rubinstazjn
- Service de Réanimation Chirurgicale Pédiatrique, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France
| | - C Glorion
- Service de Chirurgie Orthopédique et Traumatologie Pédiatrique, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France
| | - S El Messaoudi
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France
| | - D Drummond
- Service de Pneumologie Pédiatrique, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France
| | - V Lopez
- Service de Réanimation Cardiaque Pédiatrique, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France
| | - J Toubiana
- Service de Pédiatrie Générale - Équipe Mobile D'infectiologie, Hôpital Necker Enfants Malades, AP-HP, Université de Paris, 149 Rue de Sèvres, 75015, Paris, France
| | - A Béranger
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France.,Service de Réanimation et Surveillance Continue Médico-Chirurgicales Pédiatriques, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France
| | - Sana Boujaafar
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France.,Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France
| | - Yi Zheng
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France.,Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France
| | - Carmen Capito
- Service de Chirurgie Viscérale et Urologique Pédiatriques, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France
| | - S Winter
- Service d'hématologie, Immunologie et Rhumatologie Pédiatrique Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France
| | - P L Léger
- Service de Réanimation Pédiatrique, Hôpital Armand Trousseau, 26 Avenue du Dr Arnold Netter, 75012, Paris, France
| | - R Berthaud
- Service de Néphrologie Pédiatrique, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75015, Paris, France.,Unite de Recherche Clinique Paris Descartes Necker Cochin, AP-HP, 89 rue d'Assas, 75014, Paris, France.,CIC-1419 Inserm, Cochin-Necker, 149 Rue de Sèvres, 75015, Paris, France
| | - Inès Gana
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France.,Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France
| | - F Foissac
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France.,Unite de Recherche Clinique Paris Descartes Necker Cochin, AP-HP, 89 rue d'Assas, 75014, Paris, France.,CIC-1419 Inserm, Cochin-Necker, 149 Rue de Sèvres, 75015, Paris, France
| | - J M Tréluyer
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France.,Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.,Unite de Recherche Clinique Paris Descartes Necker Cochin, AP-HP, 89 rue d'Assas, 75014, Paris, France.,CIC-1419 Inserm, Cochin-Necker, 149 Rue de Sèvres, 75015, Paris, France
| | - N Bouazza
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France.,Unite de Recherche Clinique Paris Descartes Necker Cochin, AP-HP, 89 rue d'Assas, 75014, Paris, France.,CIC-1419 Inserm, Cochin-Necker, 149 Rue de Sèvres, 75015, Paris, France
| | - S Benaboud
- EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France.,Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France
| |
Collapse
|
6
|
Béranger A, Benaboud S, Urien S, Nguyen-Khoa T, Gana I, Toubiana J, Zheng Y, Lesage F, Renolleau S, Hirt D, Tréluyer JM, Oualha M. Estimation of piperacillin clearance with different glomerular filtration rate formulas in critically ill children. Br J Clin Pharmacol 2020; 87:1275-1281. [PMID: 32737909 DOI: 10.1111/bcp.14505] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2020] [Revised: 06/29/2020] [Accepted: 07/17/2020] [Indexed: 11/26/2022] Open
Abstract
AIMS Glomerular filtration rate (GFR) is difficult to assess in critically ill children using gold standard method and alternatives are needed. This study aimed to determine the most accurate GFR estimation formula for assessing piperacillin clearance in critically ill children, using a published piperacillin pharmacokinetics (PK) population model. METHODS All children hospitalized in the paediatric intensive care unit of a single institution who were receiving piperacillin were included. PK were described using the nonlinear mixed effect modelling software MONOLIX. In the initial PK model, GFR was estimated according to the Schwartz 1976 formula. We evaluated a set of 12 additional validated formulas, developed using plasma creatinine and/or cystatin C concentrations, in the building model to assess the lowest between-subject variability for piperacillin clearance. RESULTS We included 20 children with a median (range) postnatal age of 1.9 (0.1-19) years, body weight of 12.5 (3.5-69) kg. Estimated GFR according to the Schwartz 1976 formula was 160.5 (38-315) mL min-1 1.73 m-2 . Piperacillin clearance was best predicted by the Bouvet combined formula. CONCLUSION The combined Bouvet formula was the most accurate GFR estimation formula for assessing piperacillin clearance in critically ill children.
Collapse
Affiliation(s)
- Agathe Béranger
- Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Université de Paris, Paris, France.,Service de réanimation et surveillance continue médico-chirurgicales pédiatriques, Hôpital Necker Enfants Malades, AP-HP, Université de Paris, Paris, France
| | - Sihem Benaboud
- Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Université de Paris, Paris, France.,Service de pharmacologie clinique, Hôpital Cochin, AP-HP, Université de Paris, Paris, France
| | - Saïk Urien
- Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Université de Paris, Paris, France.,Unité de Recherche Clinique - Centre d'Investigation Clinique 1419, Hôpital Cochin-Necker, Université de Paris, Inserm, Paris, France
| | - Thao Nguyen-Khoa
- Laboratoire de biochimie générale, Hôpital Necker Enfants Malades, AP-HP, Université de Paris, Paris, France
| | - Inès Gana
- Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Université de Paris, Paris, France.,Service de pharmacologie clinique, Hôpital Cochin, AP-HP, Université de Paris, Paris, France
| | - Julie Toubiana
- Service de pédiatrie générale - équipe mobile d'infectiologie, hôpital Necker Enfants Malades, AP-HP, Université de Paris, Paris, France
| | - Yi Zheng
- Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Université de Paris, Paris, France.,Service de pharmacologie clinique, Hôpital Cochin, AP-HP, Université de Paris, Paris, France
| | - Fabrice Lesage
- Service de réanimation et surveillance continue médico-chirurgicales pédiatriques, Hôpital Necker Enfants Malades, AP-HP, Université de Paris, Paris, France
| | - Sylvain Renolleau
- Service de réanimation et surveillance continue médico-chirurgicales pédiatriques, Hôpital Necker Enfants Malades, AP-HP, Université de Paris, Paris, France
| | - Déborah Hirt
- Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Université de Paris, Paris, France.,Service de pharmacologie clinique, Hôpital Cochin, AP-HP, Université de Paris, Paris, France
| | - Jean-Marc Tréluyer
- Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Université de Paris, Paris, France.,Service de pharmacologie clinique, Hôpital Cochin, AP-HP, Université de Paris, Paris, France.,Unité de Recherche Clinique - Centre d'Investigation Clinique 1419, Hôpital Cochin-Necker, Université de Paris, Inserm, Paris, France
| | - Mehdi Oualha
- Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Université de Paris, Paris, France.,Service de réanimation et surveillance continue médico-chirurgicales pédiatriques, Hôpital Necker Enfants Malades, AP-HP, Université de Paris, Paris, France
| |
Collapse
|
7
|
Collet A, Baes D, Mambie A, Hembert K, Boulle C, Gana I, Lemaire X. VZV meningoencephalitis treated with ganciclovir. Med Mal Infect 2020; 50:444-445. [DOI: 10.1016/j.medmal.2020.03.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Revised: 09/09/2019] [Accepted: 03/02/2020] [Indexed: 11/26/2022]
|
8
|
Contejean A, Jaffrelot L, Benaboud S, Tréluyer JM, Grignano E, Willems L, Gauzit R, Bouscary D, Gana I, Boujaafar S, Kernéis S, Hirt D. A meropenem pharmacokinetics model in patients with haematological malignancies. J Antimicrob Chemother 2020; 75:2960-2968. [DOI: 10.1093/jac/dkaa275] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Accepted: 05/19/2020] [Indexed: 02/03/2023] Open
Abstract
Abstract
Background
Optimal dosing of antibiotics is critical in immunocompromised patients suspected to have an infection. Data on pharmacokinetics (PK) of meropenem in patients with haematological malignancies are scarce.
Objectives
To optimize dosing regimens, we aimed to develop a PK population model for meropenem in this population.
Methods
Patients aged ≥18 years, hospitalized in the haematology department of our 1500 bed university hospital for a malignant haematological disease and who had received at least one dose of meropenem were eligible. Meropenem was quantified by HPLC. PK were described using a non-linear mixed-effect model and external validation performed on a distinct database. Monte Carlo simulations estimated the PTA, depending on renal function, duration of infusion and MIC. Target for free trough concentration was set at >4× MIC.
Results
Overall, 88 patients (181 samples) were included, 66 patients (75%) were in aplasia and median Modification of Diet in Renal Disease (MDRD) CLCR was 117 mL/min/1.73 m2 (range: 35–359). Initial meropenem dosing regimen ranged from 1 g q8h to 2 g q8h over 30 to 60 min. A one-compartment model with first-order elimination adequately described the data. Only MDRD CLCR was found to be significantly associated with CL. Only continuous infusion achieved a PTA of 100% whatever the MIC and MDRD CLCR. Short duration of infusion (<60 min) failed to reach an acceptable PTA, except for bacteria with MIC < 0.25 mg/L in patients with MDRD CLCR below 90 mL/min/1.73 m2.
Conclusions
In patients with malignant haematological diseases, meropenem should be administered at high dose (6 g/day) and on continuous infusion to reach acceptable trough concentrations.
Collapse
Affiliation(s)
- A Contejean
- Service d’Hématologie, AP-HP, Hôpital Cochin, Paris, France
- Equipe mobile d’infectiologie, AP-HP, Centre Université de Paris—Cochin, Paris, France
| | - L Jaffrelot
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
| | - S Benaboud
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
| | - J -M Tréluyer
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
- CIC-1419 Inserm, Cochin-Necker, Paris, France
| | - E Grignano
- Service d’Hématologie, AP-HP, Hôpital Cochin, Paris, France
- Université de Paris, Faculté de Médecine, Paris, France
| | - L Willems
- Service d’Hématologie, AP-HP, Hôpital Cochin, Paris, France
| | - R Gauzit
- Equipe mobile d’infectiologie, AP-HP, Centre Université de Paris—Cochin, Paris, France
| | - D Bouscary
- Service d’Hématologie, AP-HP, Hôpital Cochin, Paris, France
- Université de Paris, Faculté de Médecine, Paris, France
| | - I Gana
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
| | - S Boujaafar
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
| | - S Kernéis
- Université de Paris, Faculté de Médecine, Paris, France
- Equipe mobile d’infectiologie, AP-HP, Centre Université de Paris—Cochin, Paris, France
| | - D Hirt
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
- INSERM, U1018, Université Paris-Sud, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
9
|
Salvador E, Oualha M, Bille E, Beranger A, Moulin F, Benaboud S, Boujaafar S, Gana I, Urien S, Zheng Y, Toubiana J, Briand C, Bustarret O, Geslain G, Renolleau S, Treluyer JM, Hirt D. Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus. Clin Microbiol Infect 2020; 27:413-419. [PMID: 32360445 DOI: 10.1016/j.cmi.2020.04.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2020] [Revised: 03/27/2020] [Accepted: 04/21/2020] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Cefazolin is one of curative treatments for infections due to methicillin-sensitive Staphylococcus aureus (MSSA). Both growth and critical illness may impact the pharmacokinetic (PK) parameters. We aimed to build a population PK model for cefazolin in critically ill children in order to optimize individual dosing regimens. METHODS We included all children (age < 18 years, body weight (BW) > 2.5 kg) receiving cefazolin for MSSA infection. Cefazolin total plasma concentrations were quantified by high-performance liquid chromatography. A data modelling process was performed with the software MONOLIX. Monte Carlo simulations were used in order to attain the PK target of 100% fT > 4 ×MIC. RESULTS Thirty-nine patients with a median (range) age of 7 (0.1-17) years and a BW of 21 (2.8-79) kg were included. The PK was ascribed to a one-compartment model, where typical clearance and volume of distribution estimations were 1.4 L/h and 3.3 L respectively. BW, according to the allometric rules, and estimated glomerular filtration rate (eGFR) on clearance were the two influential covariates. Continuous infusion with a dosing of 100 mg/kg/day to increase to 150 mg/kg/day for children with a BW < 10 kg or eGFR >200 mL/min/1.73m2 were the best schemes to reach the PK target of 100% fT> 4 ×MIC. CONCLUSIONS In critically ill children infected with MSSA, continuous infusion seems to be the most appropriate scheme to reach the PK target of 100 % fT > 4 ×MIC in children with normal and augmented renal function.
Collapse
Affiliation(s)
- E Salvador
- Department of Paediatric Intensive Care Unit, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France; Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France.
| | - M Oualha
- Department of Paediatric Intensive Care Unit, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France; Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France
| | - E Bille
- Microbiological Laboratory, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France
| | - A Beranger
- Department of Paediatric Intensive Care Unit, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France; Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France
| | - F Moulin
- Microbiological Laboratory, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France
| | - S Benaboud
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France; Department of Clinical Pharmacology, Cochin Hospital, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France
| | - S Boujaafar
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France; Department of Clinical Pharmacology, Cochin Hospital, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France
| | - I Gana
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France; Department of Clinical Pharmacology, Cochin Hospital, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France
| | - S Urien
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France
| | - Y Zheng
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France; Department of Clinical Pharmacology, Cochin Hospital, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France
| | - J Toubiana
- Department of General Paediatrics and Paediatric Infectious Diseases, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France
| | - C Briand
- Department of Paediatric Immunohaematology, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France
| | - O Bustarret
- Department of Surgical Paediatric Intensive Care Unit, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France
| | - G Geslain
- Department of Surgical Paediatric Intensive Care Unit, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France
| | - S Renolleau
- Department of Paediatric Intensive Care Unit, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France
| | - J-M Treluyer
- Department of Paediatric Intensive Care Unit, Necker Enfants Malades Hospital, Paris Descartes University, Sorbonne-Paris Cité, 149 Rue de Sèvres, 75015, Paris, France; Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France; Department of Clinical Pharmacology, Cochin Hospital, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France
| | - D Hirt
- Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France; Department of Clinical Pharmacology, Cochin Hospital, Paris Descartes University, 27 Rue Du Faubourg Saint Jacques, 75014, Paris, France
| |
Collapse
|
10
|
Zheng Y, Aboura R, Boujaafar S, Lui G, Hirt D, Bouazza N, Foissac F, Treluyer JM, Benaboud S, Gana I. HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma. J Pharm Biomed Anal 2020; 182:113119. [PMID: 32004775 DOI: 10.1016/j.jpba.2020.113119] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 11/26/2019] [Accepted: 01/17/2020] [Indexed: 11/30/2022]
Abstract
Therapeutic drug monitoring (TDM) is essential in the optimization of antiretroviral (ARV) treatments. In this work, we describe a new method for the simultaneous quantification of six molecules: the three novel ARV agents dolutegravir (DTG), elvitegravir (ELV) and rilpivirine (RPV), the first integrase inhibitor raltegravir (RAL) and its major metabolite the raltegravir-β-d-glucuronide (RAL-GLU), an protease inhibitor darunavir (DRV) and its booster ritonavir (RTV) in human plasma. The drugs were extracted from 100 μL of plasma by a simple method of protein precipitation using acetonitrile. The separation was carried out on a Kinetex phehyl-hexyl column using a phase mobile composed of 55 % of water (0.05 % formic acid,v/v) and 45 % of methanol (0.05 % formic acid,v/v). The flow rate was set at 0.5 mL/min. The calibration ranged from 60 to 15000 ng/mL for DRV, from 20 to 5000 ng/mL for DTG and ELV, from 10 to 2500 ng/mL for RAL, RAL-GLU, RTV and RPV. The proposed method was validated with a good precision (inter- and intra-day CV% inferior to 12.3 %) and a good accuracy (inter- and intra-day bias between -9.9 % and 10 %) for all the analytes. The proposed method is simple, reliable and suitable for therapeutic drug monitoring (TDM) and for pharmacokinetics studies.
Collapse
Affiliation(s)
- Yi Zheng
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France; EA 7323, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France; Unité de Recherche Clinique Paris Descartes Necker Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France.
| | - Radia Aboura
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France
| | - Sana Boujaafar
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France
| | - Gabrielle Lui
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France; EA 7323, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France; Unité de Recherche Clinique Paris Descartes Necker Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Déborah Hirt
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France; EA 7323, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France; Unité de Recherche Clinique Paris Descartes Necker Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Naïm Bouazza
- EA 7323, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France; Unité de Recherche Clinique Paris Descartes Necker Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Frantz Foissac
- EA 7323, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France; Unité de Recherche Clinique Paris Descartes Necker Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Jean-Marc Treluyer
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France; EA 7323, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France; Unité de Recherche Clinique Paris Descartes Necker Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Sihem Benaboud
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France; EA 7323, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France; Unité de Recherche Clinique Paris Descartes Necker Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Inès Gana
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France
| |
Collapse
|
11
|
Zheng Y, Wang Z, Lui G, Hirt D, Treluyer J, Benaboud S, Aboura R, Gana I. Simultaneous quantification of levofloxacin, pefloxacin, ciprofloxacin and moxifloxacin in microvolumes of human plasma using high‐performance liquid chromatography with ultraviolet detection. Biomed Chromatogr 2019; 33:e4506. [DOI: 10.1002/bmc.4506] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Revised: 12/22/2018] [Accepted: 02/05/2019] [Indexed: 12/20/2022]
Affiliation(s)
- Yi Zheng
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de ParisGroupe Hospitalier Paris Centre Paris France
- EA 7323Université Paris Descartes Paris France
- Unité de Recherche Clinique Paris Descartes Necker CochinAssistance Publique des Hôpitaux de Paris Paris France
| | - Ziqing Wang
- EA 7323Université Paris Descartes Paris France
| | - Gabrielle Lui
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de ParisGroupe Hospitalier Paris Centre Paris France
- EA 7323Université Paris Descartes Paris France
- Unité de Recherche Clinique Paris Descartes Necker CochinAssistance Publique des Hôpitaux de Paris Paris France
| | - Déborah Hirt
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de ParisGroupe Hospitalier Paris Centre Paris France
- EA 7323Université Paris Descartes Paris France
- Unité de Recherche Clinique Paris Descartes Necker CochinAssistance Publique des Hôpitaux de Paris Paris France
| | - Jean‐Marc Treluyer
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de ParisGroupe Hospitalier Paris Centre Paris France
- EA 7323Université Paris Descartes Paris France
- Unité de Recherche Clinique Paris Descartes Necker CochinAssistance Publique des Hôpitaux de Paris Paris France
| | - Sihem Benaboud
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de ParisGroupe Hospitalier Paris Centre Paris France
- EA 7323Université Paris Descartes Paris France
- Unité de Recherche Clinique Paris Descartes Necker CochinAssistance Publique des Hôpitaux de Paris Paris France
| | - Radia Aboura
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de ParisGroupe Hospitalier Paris Centre Paris France
- Unité de Recherche Clinique Paris Descartes Necker CochinAssistance Publique des Hôpitaux de Paris Paris France
| | - Inès Gana
- Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique des Hôpitaux de ParisGroupe Hospitalier Paris Centre Paris France
- Unité de Recherche Clinique Paris Descartes Necker CochinAssistance Publique des Hôpitaux de Paris Paris France
| |
Collapse
|
12
|
Gana I, Barrio M, Ghaddar C, Nicolaï B, Do B, Tamarit JL, Safta F, Rietveld IB. An Integrated View of the Influence of Temperature, Pressure, and Humidity on the Stability of Trimorphic Cysteamine Hydrochloride. Mol Pharm 2015; 12:2276-88. [DOI: 10.1021/mp500830n] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Inès Gana
- Caractérisation
des Matériaux Moléculaires à Activité
Thérapeutique (CAMMAT), Faculté de Pharmacie, Université Paris Descartes, 4, Avenue de l’Observatoire, 75006 Paris, France
- Laboratoire
de chimie analytique, Faculté de Pharmacie, Université de Monastir, rue Ibn Sina, 5000 Monastir, Tunisie
| | - Maria Barrio
- Grup
de Caracterització de Materials (GCM), Departament de Física
i Enginyeria Nuclear, Universitat Politècnica de Catalunya, ETSEIB, Diagonal 647, 08028 Barcelona, Spain
| | - Carine Ghaddar
- Etablissement
Pharmaceutique de l’Assistance Publique-Hôpitaux de
Paris, Agence Générale des Equipements et Produits de Santé, 7, rue du Fer à Moulin, 75005 Paris, France
| | - Béatrice Nicolaï
- Caractérisation
des Matériaux Moléculaires à Activité
Thérapeutique (CAMMAT), Faculté de Pharmacie, Université Paris Descartes, 4, Avenue de l’Observatoire, 75006 Paris, France
| | - Bernard Do
- Etablissement
Pharmaceutique de l’Assistance Publique-Hôpitaux de
Paris, Agence Générale des Equipements et Produits de Santé, 7, rue du Fer à Moulin, 75005 Paris, France
| | - Josep-Lluís Tamarit
- Grup
de Caracterització de Materials (GCM), Departament de Física
i Enginyeria Nuclear, Universitat Politècnica de Catalunya, ETSEIB, Diagonal 647, 08028 Barcelona, Spain
| | - Fathi Safta
- Laboratoire
de chimie analytique, Faculté de Pharmacie, Université de Monastir, rue Ibn Sina, 5000 Monastir, Tunisie
| | - Ivo B. Rietveld
- Caractérisation
des Matériaux Moléculaires à Activité
Thérapeutique (CAMMAT), Faculté de Pharmacie, Université Paris Descartes, 4, Avenue de l’Observatoire, 75006 Paris, France
| |
Collapse
|
13
|
Gana I, Barrio M, Do B, Tamarit JL, Céolin R, Rietveld IB. Benzocaine polymorphism: pressure-temperature phase diagram involving forms II and III. Int J Pharm 2013; 456:480-8. [PMID: 23994015 DOI: 10.1016/j.ijpharm.2013.08.031] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Revised: 08/13/2013] [Accepted: 08/15/2013] [Indexed: 11/19/2022]
Abstract
Understanding the phase behavior of an active pharmaceutical ingredient in a drug formulation is required to avoid the occurrence of sudden phase changes resulting in decrease of bioavailability in a marketed product. Benzocaine is known to possess three crystalline polymorphs, but their stability hierarchy has so far not been determined. A topological method and direct calorimetric measurements under pressure have been used to construct the topological pressure-temperature diagram of the phase relationships between the solid phases II and III, the liquid, and the vapor phase. In the process, the transition temperature between solid phases III and II and its enthalpy change have been determined. Solid phase II, which has the highest melting point, is the more stable phase under ambient conditions in this phase diagram. Surprisingly, solid phase I has not been observed during the study, even though the scarce literature data on its thermal behavior appear to indicate that it might be the most stable one of the three solid phases.
Collapse
Affiliation(s)
- Inès Gana
- EAD Physico-chimie Industrielle du Médicament (EA4066), Faculté de Pharmacie, Université Paris Descartes, 4, Avenue de l'Observatoire, 75006 Paris, France; Etablissement Pharmaceutique de l'Assistance Publique-Hôpitaux de Paris, Agence Générale des Equipements et Produits de Santé, 7, rue du Fer à Moulin, 75005 Paris, France; Laboratoire de chimie analytique, Faculté de Pharmacie, rue Ibn Sina, 5000 Monastir, Tunisia
| | | | | | | | | | | |
Collapse
|
14
|
Rotival R, Corvis Y, Cartigny Y, Négrier P, Marchivie M, Massip S, Gana I, Lemoine P, Espeau P. Comprehensive determination of the solid state stability of bethanechol chloride active pharmaceutical ingredient using combined analytical tools. CrystEngComm 2013. [DOI: 10.1039/c3ce40707a] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|